Brief: Immuneering Reports FDA Clearance Of IND Application For Early-Stage Trial Of Solid Tumors Therapy
30/09/2022 12:15
Sept 30 (Reuters) - Immuneering Corp IMRX.O :
* IMMUNEERING ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR
PHASE
1/2A CLINICAL TRIAL OF IMM-1-104 TO TREAT ADVANCED SOLID TUMORS
WITH RAS MUTATIONS
* IMMUNEERING CORP - EXPECTS ENROLLING FIRST PATIENT IN Q4
OF 2022
Source text for Eikon: ID:nGNX9n2C4c
Further company coverage: IMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences